Efficacy is the primary factor in patients’ decisions to take antipsychotic medications, but weight gain is an important side effect that can also impact those decisions, explained Adam Simmons, director of clinical program management, Alkermes. Simmons was interviewed at the 175th Annual Meeting of the American Psychiatric Association, where he presented on the investigational drug ALKS 3831.
Efficacy is the primary factor in patients’ decisions to take antipsychotic medications, but weight gain is an important side effect that can also impact those decisions, explained Adam Simmons, director of clinical program management, Alkermes. Simmons was interviewed at the 175th Annual Meeting of the American Psychiatric Association, where he presented on the investigational drug ALKS 3831.
Transcript
Are there patient-reported outcomes indicating that more people will stay on therapy if they receive the benefits of olanzapine with less weight gain?
Yeah, interestingly, we did a survey of 500 patients living with schizophrenia being treated in outpatient clinics asking about what their preferences were for antipsychotic medications in general. Some of the feedback from that survey was that, first and foremost, efficacy was the most important factor for them taking a medication.
But when we asked about side effects, weight gain was one of the most important side effects for them to consider in taking a medication. Further to that, we asked about thresholds of weight gain, and about 80% of patients will go onto a medication, if that medication’s gonna cause about 5 pounds or less of weight gain.
But as you kind of go up the threshold and you start asking about 20 pounds or more, that’s where we know that for 70% of patients, they either absolutely won’t take a medication or it would seriously impact their decision. And with that, that number was even higher for females. So based on that survey as well as other information that’s been published in the literature, we know that weight gain is a major factor in people’s decision for choosing whether or not to take a certain antipsychotic medication.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
VBID, Heading Into a Third Decade, Looks to Promote Personalization and Access
March 12th 2025Speakers at the 2025 Value-Based Insurance Design summit recapped the accomplishments made over the past 20 years in designing insurance benefits with value in mind and looked ahead to iterations to come.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Advancing HIV Care With Doravirine and Islatravir: Q&A With Amy Colson, MD, MPH
March 12th 2025New data from the MK-8591A-051 and MK-8591A-052 trials, both investigating the efficacy and safety of 100-mg doravirine and 0.25-mg islatravir as a once-daily 2-drug regimen for virologically suppressed people living with HIV-1, were presented today by Amy Colson, MD, MPH.
Read More
Implementation, Adherence to DoxyPEP Remains Low in At-Risk Groups
March 12th 2025Patients in Washington D.C. and San Francisco had minimal early uptake and adherence to doxycycline post-exposure prophylaxis (DoxyPEP) in studies presented at the Conference on Retroviruses and Opportunistic Infections 2025.
Read More